|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Interest-bearing deposits with banks | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted investments in bank stocks | ||||||||||||||||||||
| Securities available-for-sale (amortized cost of $973,712 and $972,138 at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Loans held for sale, at fair value | ||||||||||||||||||||
| Loans | ||||||||||||||||||||
| Less: Allowance for credit losses | ||||||||||||||||||||
| Net loans | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Cash surrender value of life insurance | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Deferred tax assets, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Deposits: | ||||||||||||||||||||
| Noninterest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Deposits held for assumption in connection with sale of bank branch | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Securities sold under agreements to repurchase and federal funds purchased | ||||||||||||||||||||
| FHLB advances and other borrowings | ||||||||||||||||||||
| Subordinated notes and trust preferred debt | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ Equity | ||||||||||||||||||||
| Preferred stock, $1.25 par value per share; 500,000 shares authorized; no shares issued or outstanding | ||||||||||||||||||||
| Common stock, no par value—$0.05205 stated value per share; 50,000,000 shares authorized; 19,710,341 shares issued and 19,669,802 outstanding at June 30, 2026; 19,711,628 shares issued and 19,507,208 outstanding at December 31, 2025 | ||||||||||||||||||||
| Additional paid - in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock—211,364 and 332,673 shares, at cost at September 30, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Treasury stock—40,539 and 204,420 shares, at cost at June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
